CVRTI Metabolism Program

Laboratories in the CVRTI Metabolism Program investigate how alterations in bioenergetics contribute to various adult, congenital, and inherited forms of heart failure, using a combination of cutting-edge imaging, proteomic, metabolomic, and electrophysiological techniques.

The program consists of Dipayan Chaudhuri, MD, PhD (Director), Sarah Franklin, PhD, Guillaume Hoareau, DVM, PhD, and Joseph Palatinus, MD, PhD. The Chaudhuri Lab is exploring how altering mitochondrial ion transport may be a potential therapy for heart failure and metabolic diseases. The Franklin Lab’s research provides deep insights into how the control of transcription alters the progression of cardiac disease, partly via the control of metabolic pathways. The Hoareau Lab is focused on mitochondria-targeting therapies that prevent hemorrhagic shock and cardiac ischemia-reperfusion injury, particularly in military warfighters. The Palatinus Lab is focused on understanding how metabolic dysfunction triggers inflammation in arrhythmogenic cardiomyopathy, a genetic heart disease with no treatments available, where healthy cardiac tissue is slowly replaced by scar and fat. These groups with complementary skills share a common goal of developing potential therapies by identifying new pathways at the intersection of metabolism and heart failure.